Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6474882 | 1.00 | MEN1 (0.51) | MEN1KMT2ALMNATNKSCYP2C9 | |
| SCHEMBL3892833 | 1.00 | MEN1 (0.51) | MEN1KMT2ALMNATNKSCYP2C9 | |
| SCHEMBL10163879 | 0.81 | LMNA (0.47) | MEN1KMT2ALMNATNKS | |
| SCHEMBL542561 | 0.78 | LMNA (0.53) | MEN1KMT2ALMNATNKSCYP2C9 | |
| SCHEMBL20134878 | 0.78 | LMNA (0.53) | MEN1KMT2ALMNATNKSCYP2C9 | |
| SCHEMBL17054772 | 0.77 | MEN1 (0.55) | MEN1KMT2ALMNATNKS | |
| SCHEMBL204119 | 0.77 | LMNA (0.51) | MEN1KMT2ALMNATNKSCYP2C9 | |
| SCHEMBL6135313 | 0.77 | LMNA (0.51) | MEN1KMT2ALMNATNKSCYP2C9 | |
| SCHEMBL17570773 | 0.77 | LMNA (0.51) | MEN1KMT2ALMNATNKS | |
| SCHEMBL4385865 | 0.77 | LMNA (0.51) | MEN1KMT2ALMNATNKSCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168666-B2 | Substituted carbinol compound | KOWA COMPANY, LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| EP-2098515-B1 | SUBSTITUTED CARBINOL COMPOUND | KOWA CO (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20100063119-A1 | SUBSTITUTED CARBINOL COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2098515-A1 | SUBSTITUTED CARBINOL COMPOUND | Kowa Company. Ltd. (JP) | 2009-09-09 | — | — | EP | disclosed |
| EP-0905139-B1 | 5 ring heterocyles, process for preparation, use as inhibitors of leukocyte adhesion and pharmaceutical preparations comprising them | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-01-21 | — | — | EP | disclosed |
| EP-0816343-B1 | Process for the preparation of chiral, non-racemic (4-aryl-2,5-dioxoimidazolidin-1-yl)-acetic acids | SANOFI AVENTIS DEUTSCHLAND (DE) | 2005-12-14 | — | — | EP | disclosed |
| US-6838439-B2 | Heterocytes as inhibitors of leucocyte adhesion and as VLA-4 antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-04 | — | — | US | disclosed |
| US-20040220148-A1 | 5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| EP-0842944-B1 | Heterocycles as inhibitors of leukocyte adhesion and as antagonists of VLA-4 | HOECHST AG (DE) | 2003-07-09 | — | — | EP | disclosed |
| EP-0842943-B1 | 5-Ring heterocycles as inhibitors of leukocyte adhesion and as VLA-4 antagonists | HOECHST AG (DE) | 2003-02-26 | — | — | EP | disclosed |
| US-6018053-A | Process for the preparation of chiral, nonracemic (4-aryl-2,5-dioxoimidazolidin-1-yl) acetic acids | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-01-25 | — | — | US | disclosed |
| US-5998447-A | ANTIINFLAMMATORY AGENTS | HOECHST AKTIENGESELLSCHAFT AG (DE) | 1999-12-07 | — | — | US | disclosed |
| US-5981492-A | ADMINISTERED TO THE PATIENT TO INHIBIT THROMBOCYTE AGGREGATION, THE METASTASIZATION OF CARCINOMA CELLS, THE BINDING OF OSTEOCLASTS TO THE BONE SURFACE, OR FOR THE TREATMENT OF THROMBOSES | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-11-09 | — | — | US | disclosed |
| US-5939556-A | Hydantoin compounds, salts thereof, processes for their preparation, and processes for preparing pharmaceutically active compounds comprising them | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-08-17 | — | — | US | disclosed |
| EP-0905139-A2 | 5 ring heterocyles, process for preparation, use as inhibitors of leukocyte adhesion and pharmaceutical preparations comprising them | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-03-31 | — | — | EP | disclosed |
| EP-0842945-A2 | Heterocycles as inhibitors of leukocyte adhesion and as antagonists of VLA-4 | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-20 | — | — | EP | disclosed |
| EP-0842943-A2 | 5-Ring heterocycles as inhibitors of leukocyte adhesion and as VLA-4 antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-20 | — | — | EP | disclosed |
| EP-0842944-A2 | Heterocycles as inhibitors of leukocyte adhesion and as antagonists of VLA-4 | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-20 | — | — | EP | disclosed |
| EP-0816343-A1 | Process for the preparation of chiral, non-racemic (4-aryl-2,5-dioxoimidazolin-1-yl)-acetic acids | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-01-07 | — | — | EP | disclosed |
| WO-1995014008-A1 | SUBSTITUTED 5-RING HETEROCYCLES, THEIR PREPARATION AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220148-A1 | 5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | VCAM1, LTB4R, ITGB4 | MEN1 4547/4885KMT2A 2615/4885LMNA 1233/4885 |
| US-20100063119-A1 | SUBSTITUTED CARBINOL COMPOUND | NR1H2, NR1H3, CYP46A1 | MEN1 3926/4885KMT2A 1414/4885LMNA 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.